Jeffrey S. Glenn

All filings by Jeffrey S. Glenn on record concern Eiger BioPharmaceuticals, Inc., in the capacity of board member. In total, 2 filings cover trades dated from 11 March 2022 to 22 December 2022.

The open-market record is one-sided, with 1 purchase worth €121k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant.

The latest filing, published on 27 December 2022, reports an open-market purchase of €121k in Eiger BioPharmaceuticals, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.